Skip to content

Treatment of Elevated Blood Pressures in Early Pregnancy

Treatment of Elevated Blood Pressures in Early Pregnancy

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05955040
Enrollment
2
Registered
2023-07-20
Start date
2023-07-11
Completion date
2024-05-06
Last updated
2024-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated Blood Pressure, Pregnancy Induced Hypertension

Brief summary

This is a randomized controlled trial comparing the outcomes of treatment and non-treatment of elevated blood pressures in early pregnancy.

Detailed description

Patients will be randomized to treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic) versus non-treatment. After randomization to treatment, patient's will be treated with either nifedipine or labetalol (both medications that are standard of care for treatment of elevated blood pressure during pregnancy). The purpose of this study is two-fold: 1) Determine if treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic) versus non-treatment improves maternal and fetal outcomes and 2) determine if ICG directed treatment is optimal as ICG will not be used to determine treatment medication (this will be done by secondary analysis after conclusion of the study).

Interventions

DRUGNifedipine

Standard of care for treatment of elevated blood pressure during pregnancy

DRUGLabetalol

Standard of care for treatment of elevated blood pressure during pregnancy

Sponsors

Marshall University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients presenting for obstetric care at Marshall University (Huntington office and Teays Valley office) between 12 and 16 weeks gestation with a systolic blood pressure of 120 or greater OR a diastolic blood pressure of 80 or greater. Eligibility for this study will be have blood pressures between 120-139 systolic and 80-89 diastolic. Randomization to control, labetalol, or nifedipine will be performed after patient consent.

Exclusion criteria

* Patients already be on medication for hypertension. * Patients with the diagnosis of chronic hypertension * Patients with a BP of 140 or greater systolic OR 90 or greater diastolic (this meets criteria for chronic hypertension in pregnancy). * Patients actively using any illicit substance or have history of substance use disorder. * Patients who are actively consuming alcohol during pregnancy. * Patients with Type I or Type II Diabetes Mellitus. * Patients with end stage renal disease. * Patients less then 12 weeks gestation or greater than 16 weeks

Design outcomes

Primary

MeasureTime frameDescription
Treatment of elevated blood pressuresthrough study completion, an average of 1 yearPatient age

Secondary

MeasureTime frameDescription
ICG directed treatmentthrough study completion, an average of 1 yearCompare cardiac output

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026